Trial Profile
A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bioenhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GSK
- 26 Apr 2012 Actual patient numbers changed from 10 to 20 as reported by ClinicalTrials.gov.
- 13 Jan 2012 Actual patient numbers changed from 20 to 10 as reported by ClinicalTrials.gov.
- 13 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.